Dow Up0.48% Nasdaq Up0.43%

Adherex Technologies Inc. (ADHXF)

-Other OTC
0.86 0.01(1.17%) Aug 19, 2:36PM EDT
|Pre-Market : NaN
ProfileGet Profile for:
Adherex Technologies Inc.
68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States - Map
Phone: 919-636-4530
Fax: 919-890-0490

Index Membership:N/A
Full Time Employees:1

Business Summary 

Adherex Technologies Inc., together with its subsidiaries, operates as a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. Its lead product candidates include Sodium Thiosulfate, a water soluble thiol compound, which is in phase III clinical trials that act as a chemical reducing agent for the prevention of cisplatin induced hearing loss or ototoxicity in children; and Eniluracil, an oral irreversible dihydropyrimidine dehydrogenase inhibitor for the rapid break down of 5-FU in the body, which has completed phase II clinical trials for the treatment of metastatic breast cancer. Adherex Technologies Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Adherex Technologies Inc.

Key Executives 
Mr. Rostislav Raykov , 38
Chairman and Chief Exec. Officer
Ms. Krysia Lynes , 44
Interim Chief Financial Officer
Dr. Thomas Spector Ph.D., 70
Ms. Anne McKay , 60
Regulatory Consultant
Mr. Alexander D. Smith M.S.,
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders